Forgot password?

Multiple Sclerosis - MS LifeLines

An educational and supportive community for people living with multiple sclerosis.

TEXT SIZE

aaa

"I learned to see life in a different way."

Submission criteria

Please note that only U.S. residents can participate in the Who's your LifeLine? program.

You'll need the following items for the
submission form:

  • A short essay (between 250-750 words) answering the question, "Who is your LifeLine, and why?" You can enter your essay directly into the form, or you can upload your essay in a Word document. Your essay must follow the submission guidelines below.
  • Permission from your nominee. The form asks you to certify that the person you nominate approves the nomination and is aware and approves their information being shared.
  • Contact information for yourself and your nominee, including name, phone number and email address.
  • (Optional) A photo of your nominee, JPEG format, size 100KB or smaller.

Program Guidelines

Your submission for the Who's Your LifeLine? program should abide by the following guidelines:

  • Submission cannot mention any specific medical treatment for MS (branded, generic or alternative therapies)
  • Nominators must verify that their nominee is aware and approves of their information being shared. A signed consent form will be required if your nominee is selected as a LifeLine Spotlight
  • Submission cannot mention adverse events due to medical treatment
  • Submission must focus on how the nominee meets each of the four scoring categories:
    1. Attitude/Determination: What is the nominee's attitude toward MS and how has he/she taken steps to overcome being affected by the disease (either as someone living with MS or as a caregiver/supporter)?
    2. Role Model/Inspiration: Does the nominee act as a role model to others who are affected by MS?
    3. Community Service/Involvement: Has the nominee established himself/herself as an active member in the MS community?
    4. Achievement: How has the nominee worked toward achieving his or her personal goals or helped the person with MS whom they care for to do so?
  • Submission must be within the word limit (minimum of 250 words, maximum of 750 words)

Each submission will be reviewed by a panel of three members of the MS community, and scored based on the program guidelines. From these submissions, the panel will periodically choose nominees for the LifeLine Spotlight. These inspirational individuals will be recognized on mslifelines.com, so that the MS community can benefit from your LifeLine's unique story.

Please note that all nominations will be valid for a period of one year and may be chosen as a LifeLine Spotlight at any time. After one year, nominations will be rotated out of the scoring pool and can be renominated.

Please note that by nominating your LifeLine, you are granting permission to the Who's Your LifeLine? program representative to contact you in the future regarding the status of your nomination. If your nominee is selected as a LifeLine Spotlight, a representative from Who's Your LifeLine? will contact you as well as your nominee to obtain a signed consent form and physician's signature, if applicable, before their selection can be considered final.

Brought to you by EMD Serono, Inc. and Pfizer Inc, the co-marketers of Rebif® (interferon beta-1a) in the US EMD SeronoPfizer

Prescribing Information - Medication Guide

This information is intended only for residents of the United States.

Rebif is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. Efficacy has been established in controlled studies up to 2 years in duration. Rebif is not approved for the treatment of chronic progressive multiple sclerosis. Rebif is available by prescription only in 22 mcg and 44 mcg pre-filled syringes and a titration pack.

Before beginning treatment, patients should discuss with their doctor the potential benefits and risks associated with Rebif. Let your doctor know if you have a history of depression, seizures, liver disease, thyroid problems, and blood count or bleeding problems or if you have had previous allergic reactions to medications. Tell your doctor about all medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Rebif and other medicines may affect each other causing serious side effects. Talk to your doctor before you take any new medicines. Rebif is not recommended for women who are or plan to become pregnant.

Potential serious side effects of Rebif include depression, liver problems, risk to pregnancy, injection site problems and severe allergic reactions. Allergic reactions are rare and may be associated with difficulty breathing and loss of consciousness, which requires immediate medical attention.

The most common side effects with Rebif are injection site reactions, flu-like symptoms (fever, chills, muscle aches, tiredness), depression, abdominal pain, increased liver enzymes, and blood cell count decreases. Let your doctor know immediately if you have any of these symptoms or feel sad, tired, hot or cold, experience hives, rashes, bruising, yellowing of the skin, or a change in body weight (gain or loss).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This information is not intended to replace discussions with your healthcare provider. For additional information about Rebif, please consult the Medication Guide or Prescribing Information and talk to your doctor. You can also call toll free 1-877-44-REBIF (1-877-447-3243). Rebif is available by prescription only.

MS LifeLines is an educational support service for people living with MS and their families. MS LifeLines and MS LifeLines Ambassadors are sponsored by EMD Serono, Inc. and Pfizer Inc.

Rebif, Rebiject II and MS LifeLines are registered trademarks and the Rebif logo is a trademark of EMD Serono, Inc. or its affiliates.

MS in Balance Your Life in Full is a service mark of EMD Serono, Inc. or its affiliates.

Copyright 2009 EMD Serono, Inc. All rights reserved.